To evaluate the clinical benefit of extended endocrine therapy after 5 years of adjuvant treatment with LHRHa in premenopausal women with node-positive, HR-positive early breast cancer.

Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive ...

SAN ANTONIO — Fertility preservation and/or assisted reproductive technologies do not increase the risk for short-term cancer recurrence in young women with early hormone receptor (HR)-positive breast ...

Older women with high-risk hormone receptor-positive breast cancer showed no significant survival benefit from adjuvant chemotherapy 4 or 8 years later. The chemotherapy group experienced four times ...

And so we really need more research into how to optimize these patients long-term, especially when we generally do not use menopausal hormone therapy in hormone receptor positive breast cancer.

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Advanced HR-positive breast cancer management is evolving with personalized therapies, improving disease control and quality of life. First-line treatment combines anti-estrogen therapy with CDK 4/6 ...

SAN ANTONIO – Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better ...

Please provide your email address to receive an email when new articles are posted on . Preoperative breast MRI provides no benefit in stage I or II hormone receptor-negative breast cancer. Five-year ...